Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn’s Disease in the CELEST Extension Study
- Resource Type
- Article
- Source
- In
Clinical Gastroenterology and Hepatology October 2022 20(10):2337-2346 - Subject
- Language
- ISSN
- 1542-3565